通过CDK1对USP33的酸化稳定了mTORC2组件SIN1的稳定性
Yalei Wen1,2, Caishi Zhang3, Mingchao Liang4
1Research Institute for Maternal and Child Health, The Affiliated Guangdong Second Provincial General Hospital, Postdoctoral Research Station of Traditional Chinese Medicine, School of Pharmacy, Jinan University, Guangzhou, China.
Cell death & disease
|July 22, 2025
概括
增加的SIN1表达通过稳定mTORC2.2驱动胰腺癌化学抵抗. 向CDK1-USP33轴会破坏SIN1的稳定,提高化疗敏感性,改善胰腺管道腺癌患者的生存结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 化学抵抗仍然是有效的癌症治疗的重要障碍.
- 通过SIN1调节的猛胺素复合体2 (mTORC2) 途径的哺乳动物标对细胞过程至关重要.
- 了解SIN1在胰腺管腺癌 (PDAC) 中的作用对于治疗的发展至关重要.
研究的目的:
- 调查SIN1在PDAC化学抵抗中的作用.
- 确定PDAC中SIN1稳定的主要调节机制.
- 评估针对特定的监管轴的治疗潜力.
主要方法:
- 在PDAC中,SIN1表达与患者存活率的相关性分析.
- 在PDAC模型中SIN1删除后瘤生长和化学敏感性的评估.
- 鉴定和功能验证USP33作为一个SIN1 deubiquitinase.
- 研究USP33的CDK1-介导酸化及其对SIN1.1的影响.
- 在PDAC组织中分析CDK1,USP33和SIN1表达相关性.
主要成果:
- 在PDAC中SIN1表达率升高与患者存活率降低相关.
- 删除SIN1会减少瘤的生长,并增加PDAC中对化疗的敏感性.
- 通过mTORC2-AKT的激活,USP33使SIN1脱和稳定,通过mTORC2-AKT的激活促进化学抵抗.
- CDK1酸化USP33,增强其对SIN1的活性,并推动PDAC的进展.
- 在PDAC组织中CDK1,USP33和SIN1表达之间存在显著的正相关性.
结论:
- 由CDK1进一步调节的USP33二基因酶稳定SIN1,是PDAC中驱动化学抵抗的关键机制.
- 针对CDK1-USP33轴提供了一个潜在的治疗策略来破坏SIN1.1.的稳定性.
- 这种方法可以克服PDAC中的化学抵抗,并对其他侵袭性癌症有希望.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
Anaphase Promoting Complex
3.0K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.0K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K


